Head And Neck Cancer

The FDA approved a new cetuximab dosage regimen for the treatment of patients with KRAS wild-type, EGFR-expressing colorectal cancer or squamous cell carcinoma of the head and neck, according to a press release.

April is Head and Neck Cancer Awareness Month.

The FDA cleared an investigational new drug application for the combination of AFM24 and SNK-01 in patients with solid tumors that express epidermal growth factor receptor, according to a joint press release from each agent’s manufacturer.

Patients with head and neck cancer who reported high financial toxicity at baseline appeared nearly twice as likely to experience poor outcomes, according to study results published in Oral Oncology.

Living in an area with higher levels of outdoor artificial nighttime light appeared associated with higher risk for developing thyroid cancer, according to an observational study published in Cancer.

The FDA granted breakthrough therapy designation to cabozantinib for treatment of certain patients with thyroid cancer, according to the agent’s manufacturer.

GERD appeared to increase risk for esophageal adenocarcinoma, esophageal squamous cell carcinoma and laryngeal squamous cell carcinoma, according to results of a study published in Cancer.

Roswell Park Comprehensive Cancer Center has promoted four physicians to leadership roles in its clinical research program.

Christian Hinrichs, MD, has been appointed chief of the section of cancer immunotherapy at Rutgers Cancer Institute of New Jersey.

The FDA granted accelerated approval to pralsetinib for treatment of certain patients with RET-altered thyroid cancer.